Full-Time

Product Control/ P&L Valuations Analyst

Confirmed live in the last 24 hours

Schonfeld

Schonfeld

201-500 employees

Multi-manager investment platform for diverse strategies

No salary listed

Mid

London, UK

Category
Risk Management
Finance & Banking
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Experience in P&L Reporting/Reconciliation
  • Strong knowledge of OTC derivatives including valuation and workflow
  • Experience in analyzing and reporting on P&L including the Greeks
  • Advanced Excel skills
  • Strong ownership and a track record of delivering results
  • Excellent communication skills and self-confidence to interact with stakeholders
  • Ability to handle a high volume of data in a fast-paced environment with strong attention to detail
  • Team player, proactive and willing to take on additional responsibility
  • Ability to think outside the box; using ingenuity, creativity and inventiveness to approach and solve problems
Responsibilities
  • Work closely with the Front Office trading system (Enfusion), the firm’s inhouse Geneva system and Fund Administrators to ensure the accuracy of the P&L
  • Oversee pricing and P&L processes
  • Oversee the setup of new products
  • Liaise closely with global departments across the firm to ensure accurate T+1 and Monthly P&L reporting
  • Investigate pricing and valuation differences and explain these to stakeholders
Desired Qualifications
  • VBA knowledge
  • OTC Derivatives knowledge
  • Experience with Bloomberg
  • Experience with Geneva
  • Experience with P&L review, calculation, reporting & reconciliations

Schonfeld Strategic Advisors is a multi-manager investment platform that works with internal and partner portfolio managers across four main trading strategies: quantitative, fundamental equity, tactical trading, and discretionary macro & fixed income. The firm uses proprietary technology and risk analytics to identify market opportunities and enhance investment performance. Schonfeld differentiates itself by providing portfolio managers with autonomy and support, allowing them to maximize their business value. The company's goal is to generate strong returns for institutional investors and high-net-worth individuals through strategic investments and effective risk management.

Company Size

201-500

Company Stage

N/A

Total Funding

$1.5B

Headquarters

New York City, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Schonfeld's expansion into discretionary macro & fixed income enhances its investment universe.
  • The firm's focus on proprietary technology strengthens its competitive edge in risk management.
  • Schonfeld's global portfolio diversification mitigates regional market risks.

What critics are saying

  • Leadership changes in Asia may disrupt Schonfeld's regional growth and operations.
  • Increased competition for quantitative talent could raise costs for Schonfeld.
  • Integrating new leadership like CTO Thomas DeBow may challenge technology strategy.

What makes Schonfeld unique

  • Schonfeld invests in diverse strategies: quantitative, fundamental equity, tactical trading, and discretionary macro.
  • The firm leverages proprietary technology and risk analytics for market opportunities.
  • Schonfeld offers global exposure across Americas, Europe, and Asia with multiple asset classes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Professional Development Budget

Company News

MarketBeat
Mar 22nd, 2025
Clarivate (NYSE:CLVT) Shares Down 5.5% - Time to Sell?

Schonfeld Strategic Advisors LLC acquired a new stake in Clarivate in the 4th quarter valued at about $56,000.

eFinancialCareers
Mar 18th, 2025
Hedge fund Schonfeld hires FX quant head in London from Millennium

Helder Antunes has joined Schonfeld as head of quantitative resources and development for macro and fixed income.

My Pharma Editions
Oct 14th, 2024
Inventiva annonce un financement allant jusqu’à 348 millions d’euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH | MyPharma Editions

Inventiva, société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d’autres maladies avec un besoin médical non satisfait, annonce aujourd'hui un financement immédiat de 94,1 millions d’euros et jusqu'à 348 millions d'euros (l’ « Opération

ETF Daily News
Jul 7th, 2024
iShares Russell 1000 Value ETF (NYSEARCA:IWD) Shares Acquired by BNP Paribas Financial Markets

Schonfeld Strategic Advisors LLC acquired a new stake in iShares Russell 1000 Value ETF in the third quarter valued at approximately $2,917,000.

Defense World
Jul 3rd, 2024
6,076 Shares in Thomson Reuters Co. (NYSE:TRI) Acquired by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

Schonfeld Strategic Advisors LLC purchased a new stake in Thomson Reuters in the 3rd quarter valued at approximately $709,000.